Chun-Long Li 
,
Xian-Cheng Han,
Hong Zhang,
Jin-Sheng Wu,
Bao Li
For correspondence:- Chun-Long Li Email: chunlongli274@gmail.com Tel:+865368068850
Received: 5 November 2014 Accepted: 14 March 2015 Published: 26 April 2015
Citation: Li C, Han X, Zhang H, Wu J, Li B. Effect of scopoletin on apoptosis and cell cycle arrest in human prostate cancer cells in vitro. Trop J Pharm Res 2015; 14(4):611-617 doi: 10.4314/tjpr.v14i4.8
© 2015 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To investigate the anticancer activity of scopoletin against human prostate cancer.
Methods: The anticancer activity of scopoletin was evaluated by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MMT) assay. Flow cytometry using propidium iodide and annexin V-FITC was employed to study apoptosis and cell cycle analysis. Hoechst 33258 staining was used to assess the effect of scopoletin on cell morphology and apoptotic body formation in human prostate carcinoma (LNCaP) cells via Florescence microscopy and finally Western blotting was used to evaluate the effect of scopoletin on cyclin D1 and cyclin B1 ex
Results: Scopoletin induced a dose-dependent growth inhibition in LNCaP prostate cancer cells. It induced G2/M phase growth arrest and led to an increase in the sub-G0/G1 cell population after treatment with increasing doses compared to control cells, scopoletin treatment resulted in cell shrinkage along with membrane blebbing which are characteristic features of cell apoptosis. Approximately 15.45, 32.6 and 21.71 % of the cells underwent early apoptosis after treatment with 40, 80 and 100 µM of scopoletin respectively. Cyclin D ex
Conclusion: These results reveal that scopoletin may be used as a natural chemotherapeutic agent against prostate cancer.
Archives
News Updates
Fulltext in PDF